Crescent Biopharma (CBIO) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 62 252 sessions, September 11, 2025 to September 11, 2026
- Largest daily move
- +20.8% close of February 19, 2026
- 1-year change
- +54.7% closing prices, September 11, 2025 to September 11, 2026
- 5-year change
- -72.2% closing prices, September 10, 2021 to September 11, 2026
Company Description
Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company developing oncology therapeutics for solid tumors. The company’s pipeline is built around antibody-based drug candidates, led by CR-001, a PD-1 x VEGF bispecific antibody, and includes antibody-drug conjugate programs such as CR-002 and CR-003.
Crescent focuses on multiple therapeutic modalities and established oncology targets. Its development strategy includes evaluating drug candidates as single agents and as part of combination regimens for a range of solid tumor settings. The company has described CR-001 as its lead program and as a potential immuno-oncology backbone candidate, while its ADC programs extend the pipeline into targeted drug-delivery approaches.
Pipeline and development focus
The company’s lead clinical program, CR-001, is a bispecific antibody designed to engage both PD-1 and VEGF pathways. Crescent has described the ASCEND study as a Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types. The company’s pipeline also includes ADC programs directed at validated oncology targets, including CR-002, identified as a PD-L1-targeted ADC, and CR-003, identified as an ITGB6-targeted ADC.
Crescent has reported a partnership with Kelun-Biotech that expands its pipeline and supports combination development involving CR-001 and antibody-drug conjugates. The company’s oncology work is centered on solid tumors and on therapeutic approaches that combine immuno-oncology and targeted cytotoxic payload delivery.
Corporate profile
Crescent Biopharma’s ordinary shares trade on Nasdaq under the symbol CBIO. The company is incorporated in the Cayman Islands and maintains principal offices in Waltham, Massachusetts. As a clinical-stage biotechnology issuer, Crescent’s public-company disclosures primarily center on research and development activity, clinical programs, financing, equity compensation, governance, and capital structure rather than commercial product revenue.
Stock Performance
Crescent Biopharma (CBIO) closed at $19.41 on September 11, 2026. Over the past 12 months, the price has gained 54.7%.
CBIO Metrics & Rankings
Price returns through September 11, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Crescent Biopharma has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, offering. View all CBIO news →
SEC Filings
Crescent Biopharma has filed 5 recent SEC filings, including 1 Form SCHEDULE 13G/A, 1 Form EFFECT, 1 Form POS AM, 1 Form 424B3. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CBIO SEC filings →
Insider Radar
Insider buying activity at Crescent Biopharma over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Crescent Biopharma generated $10.8M in revenue in FY2025, operating income reached -$152.6M (-1407.5% operating margin), and net income was $154K, reflecting a 1.4% net profit margin. The company generated -$71.5M in operating cash flow. With a current ratio of 6.56, the balance sheet reflects a strong liquidity position.
Upcoming Events
Morgan Stanley Chat
Initial proof-of-concept data
CR-001 PoC data
CR-003 PoC data
ASCEND proof-of-concept data
Clinical readouts begin
First vesting (1/4)
25% option vesting
Option vesting period
Monthly option vesting
Crescent Biopharma has 22 upcoming scheduled events. The next event, "Morgan Stanley Chat", is scheduled for September 14, 2026 (tomorrow). 13 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the CBIO stock price.
Short Interest History
Short interest in Crescent Biopharma (CBIO) currently stands at 3.2 million shares, down 7.2% from the previous reporting period, representing 8.7% of the float. Since September 2025, short interest has increased by 1128.1%. With 17.1 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Crescent Biopharma (CBIO) currently stands at 17.1 days, up 92% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 635.2% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 2.3 to 17.1 days.
CBIO Company Profile & Sector Positioning
Crescent Biopharma (CBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing CBIO often look at related companies in the same sector, including NeOnc Technologies Holdings, Inc. (NTHI), Kyverna Therapeutics, Inc. (KYTX), Nuvectis Pharma, Inc. (NVCT), Innate Pharma S.A. ADS (IPHA), and Caribou Biosciences, Inc. (CRBU). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CBIO's relative position within its industry.